This article is more than 5 years old. Information may no longer be current.

EyePoint launches Yutiq in US

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EyePoint Pharmaceuticals announced the commercial launch of Yutiq, an intravitreal implant containing fluocinolone acetonide, in the United States.

According to a company press release, the micro-insert is now available for ordering and delivery. Yutiq is FDA approved for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye.

“We are pleased to announce the availability of Yutiq in the U.S., which is an advancement in the treatment of chronic noninfectious posterior segment uveitis,” Nancy Lurker, president and CEO of EyePoint, said in the release.

The 3-year micro-insert is designed to release fluocinolone acetonide consistently for up to 36 months, according to the release.